Trius Therapeutics
Investor Relations Department
6310 Nancy Ridge Drive
Suite 105
San Diego, CA 92121
United States

Visit IR website
Sign-up for email alerts

NASDAQ: TSRX [1]		
Last Trade:		8.63
Trade Time:		4:10 PM ET Jun 18, 2013
Change:	0.03	(0.349%)
Day Range		8.51 - 8.69
52-Week Range		4.41 - 9.25
Volume		718,800
Market Cap. ($M)		413.135
Shares Out (M)		47.872

[1] The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections.

We have announced positive top-line results from our first Phase 3 clinical trial for tedizolid phosphate (TR-701), an IV and orally administered second generation oxazolidinone, for the treatment of serious gram-positive bacterial infections, including those caused by methicillin-resistant *Staphylococcus aureus* (MRSA). With the continuous increase in bacterial resistance to currently marketed drugs, serious infections are becoming more difficult, if not impossible to treat, and this has led to a clear need for novel therapeutics to treat multi-drug resistant bacterial infections.

Trius is headquartered in San Diego, California. We have built a strong management team with significant development and regulatory experience. Our senior management team consists of eight individuals who collectively have been involved in the development and approval of a significant number of anti-infective drugs.

… (more)

Stock Performance

Press Releases [View all]

Jun 12, 2013
Trius Therapeutics Announces Publication of Antibiotic Safety Study in Antimicrobial Agents and Chemotherapy

Jun 3, 2013
Trius Appoints Matthew Onaitis as General Counsel

May 13, 2013
Trius Announces Notice of Allowance of U.S. Patent Application Related to Tedizolid Phosphate Combination With Daptomycin

May 7, 2013
Trius Therapeutics Reports First Quarter 2013 Financial Results

Apr 29, 2013
Trius Therapeutics Presents Clinical Data on Experimental Antibiotic Tedizolid at ECCMID Meeting

Events [View all]

There are no events to display at this time. Please check back later.

Financials [View all]

First Quarter Financial Results

Mar 13, 2013
Annual Report (10-K)

Apr 15, 2013
Definitive Proxy Statement

May 8, 2013
Quarterly Report (10-Q)

Nov 7, 2012
Quarterly Report (10-Q)

Aug 7, 2012
Quarterly Report (10-Q)

Shareholder.com
A NASDAQ OMX COMPANY